Derivative Instruments

3 Months Ended

Dec. 31, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

Derivative Instruments

The Company has transactions and balances denominated in currencies other than the U.S. dollar. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. These transactions and balances, including short-term advances between the Company and its subsidiaries, subject the Company's operations to exposure from exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company mitigates the impact of potential currency transaction gains and losses on short-term intercompany advances through timely settlement of each transaction, generally within 30 days.

The Company also enters into foreign exchange contracts to reduce its exposure to currency fluctuations. Under forward contract arrangements, the Company typically agrees to purchase a fixed amount of U.S. dollars in exchange for a fixed amount of a foreign currency on specified dates with maturities of three months or less. These transactions do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of "Other loss, net" in the accompanying unaudited Consolidated Statements of Operations and are as follows for the three months ended December 31, 2016 and 2015 (in thousands):

	Three Months Ended December 31,
	2016			2015
Realized (losses) gains on derivative instruments not designated as hedging instruments	$	(1,003	)	$	275

The Company had the following notional amounts outstanding under foreign currency contracts that do not qualify for hedge accounting at December 31, 2016 and September 30, 2016 (in thousands):

December 31, 2016:

Buy Currency	Notional Amount of Buy Currency	Sell Currency	Maturity	Notional Amount of Sell Currency	Fair Value of Assets		Fair Value of Liabilities
British Pound	115	Norwegian Krone	January 2017	1,000	$	—	$	—
Japanese Yen	691	U.S. Dollar	January 2017	81,000	—		(2		)
British Pound	936	Swedish Krona	January 2017	8,600	2		—
Korean Won	1,711	U.S. Dollar	January 2017	2,062,000	—		(9		)
U.S. Dollar	22	Taiwan Dollar	January 2017	700	—		—
U.S. Dollar	5,823	Chinese Yuan	January 2017	41,000	—		(70		)
Euro	12,386	U.S. Dollar	January 2017	11,900	32		—
U.S. Dollar	2,338	British Pound	January 2017	1,910	—		(2		)
Singapore Dollar	261	U.S. Dollar	January 2017	380	—		—
U.S. Dollar	350	Israeli Shekel	January 2017	1,350	—		—
Euro	11,465	British Pound	January 2017	9,359	—		(3		)
					$	34	$	(86	)

September 30, 2016:

Buy Currency	Notional Amount of Buy Currency	Sell Currency	Maturity	Notional Amount of Sell Currency	Fair Value of Assets		Fair Value of Liabilities
British Pound	246	Swedish Krona	October 2016	2,100	$	1	$	—
U.S. Dollar	6,107	British Pound	October 2016	4,710	2		—
Euro	14,976	U.S. Dollar	October 2016	13,300	—		(40		)
U.S. Dollar	5,815	Chinese Yuan	October 2016	39,000	—		(33		)
Korean Won	2,255	U.S. Dollar	October 2016	2,488,000	1		—
Euro	8,403	British Pound	October 2016	6,500	—		(23		)
U.S. Dollar	311	Israeli Shekel	October 2016	1,169	1		—
					$	5	$	(96	)

The fair values of the forward contracts described above are recorded in the Company's accompanying unaudited Consolidated Balance Sheets as "Prepaid expenses and other current assets" and "Accrued expenses and other current liabilities".

Stock Warrant

The stock warrant was less than $0.1 million at September 30, 2016. The BioCision warrant agreement contained net share settlement provisions, which permitted the Company to pay the warrant exercise price using shares issuable under the warrant (“cashless exercise”). The value of the stock warrant fluctuated primarily in relation to the value of BioCision's underlying securities, either providing an appreciation in value or potentially expiring with no value. Gains and losses on the revaluation of the stock warrant were recognized as a component of "Other loss, net" in the accompanying unaudited Consolidated Statements of Operations.

During the first quarter of fiscal year 2017, the Company canceled the stock warrant as a portion of the non-cash consideration transferred for the acquisition of Cool Lab which was measured at fair value on the acquisition date. There were no stock warrants held by the Company at December 31, 2016. Please refer to Note 4, "Acquisitions"; Note 6, "Equity Method Investments" and Note 17 “Fair Value Measurements” for further information on the the acquisition of Cool Lab and the stock warrant.